Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Virology

• Publication date

  2016-09-21

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/JVI.01703-16PMID 27654293PMCID PMC5110174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Data processing.

  2021cited by this paper
• Structure of Influenza Virus N7: the Last Piece of the Neuraminidase “Jigsaw” Puzzle

  2014cited by this paper
• Data Processing

  2014cited by this paper
• Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding

  2013cited by this paper
• Structural basis for a class of nanomolar influenza A neuraminidase inhibitors

  2013cited by this paper
• Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses

  2013cited by this paper
• H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis

  2012cited by this paper
• Influenza Virus Neuraminidases with Reduced Enzymatic Activity That Avidly Bind Sialic Acid Receptors

  2012cited by this paper
• Efficient Transmission of Pandemic H1N1 Influenza Viruses with High-Level Oseltamivir Resistance

  2012cited by this paper
• Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

  2012cited by this paper
• Update: Influenza A (H3N2)v transmission and guidelines - five states, 2011.

  2012cited by this paper
• Mutations I117V and I117M and Oseltamivir Sensitivity of Pandemic (H1N1) 2009 Viruses

  2012cited by this paper
• Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition

  2011cited by this paper
• Limited human-to-human transmission of novel influenza A (H3N2) virus--Iowa, November 2011.

  2011cited by this paper
• Swine-origin influenza A (H3N2) virus infection in two children--Indiana and Pennsylvania, July-August 2011.

  2011cited by this paper
• Influenza A Virus N5 Neuraminidase Has an Extended 150-Cavity

  2011cited by this paper
• Combinatorial Effect of Two Framework Mutations (E119V and I222L) in the Neuraminidase Active Site of H3N2 Influenza Virus on Resistance to Oseltamivir

  2011influential reference
• Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation.

  2011cited by this paper
• Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.

  2011cited by this paper
• Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro.

  2011cited by this paper
• The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site

  2010cited by this paper
• Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance

  2010cited by this paper
• Antiviral Susceptibility of Avian and Swine Influenza Virus of the N1 Neuraminidase Subtype

  2010cited by this paper
• Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir.

  2010cited by this paper
• Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles.

  2010cited by this paper
• Oseltamivir-Resistant Influenza A Pandemic (H1N1) 2009 Virus, Hong Kong, China

  2009cited by this paper
• High prevalence of amantadine resistance among circulating European porcine influenza A viruses.

  2009influential reference
• Structural basis for oseltamivir resistance of influenza viruses.

  2009cited by this paper
• Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006–2008

  2009cited by this paper
• Structural Characterization of the 1918 Influenza Virus H1N1 Neuraminidase

  2008cited by this paper
• Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants

  2008cited by this paper
• Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.

  2007cited by this paper
• The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance.

  2007cited by this paper
• The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design

  2006cited by this paper
• Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use

  2006cited by this paper
• Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds

  2006cited by this paper
• Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.

  2006cited by this paper
• Avian flu: Isolation of drug-resistant H5N1 virus

  2005cited by this paper
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• Resistant influenza A viruses in children treated with oseltamivir: descriptive study.

  2004cited by this paper
• Oral oseltamivir treatment of influenza in children

  2001cited by this paper
• Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants

  2001cited by this paper
• Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

  2001cited by this paper
• Global epidemiology of influenza: past and present.

  2000cited by this paper
• In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.

  1999cited by this paper
• Refinement of macromolecular structures by the maximum-likelihood method.

  1997cited by this paper
• MOLREP: an Automated Program for Molecular Replacement

  1997cited by this paper
• Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en

  1997cited by this paper
• Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.

  1995cited by this paper
• Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.

  1995cited by this paper
• PROCHECK: a program to check the stereochemical quality of protein structures

  1993cited by this paper
• Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.

  1979cited by this paper
• Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination

  year unknowncited by this paper
• Resistant influenza A viruses in children treated with oseltamivir : descriptive study

  year unknowncited by this paper

• Discovery of Influenza Neuraminidase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation of Novel Chemotypes

  2025cites this paper
• Optimization of the Monoclonal Antibody 3E1 through W32I Mutation Enhances Antiviral Efficacy against Influenza Virus Subtypes H1N1 and H3N2.

  2025cites this paper
• Structural basis of broad protection against influenza virus by human antibodies targeting the neuraminidase active site via a recurring motif in CDR H3

  2025cites this paper
• SREBP2-dependent lipid droplet formation enhances viral replication and deteriorates lung injury in mice following IAV infection

  2025cites this paper
• Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase.

  2024cites this paper
• UiO-66 nanoparticles combat influenza A virus in mice by activating the RIG-I-like receptor signaling pathway

  2024cites this paper
• Exploration of Computational Aids for Effective Drug Designing and Management of Viral Diseases: A Comprehensive Review.

  2023cites this paper
• Melatonin alleviates lung injury in H1N1-infected mice by mast cell inactivation and cytokine storm suppression

  2023cites this paper
• Study on The Interaction Between Silibinin and Neuraminidase.

  2023cites this paper
• Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy

  2023cites this paper
• Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity.

  2022cites this paper
• Influenza A Virus Neuraminidase Inhibitors.

  2022cites this paper
• Structural and inhibitor sensitivity analysis of influenza B–like viral neuraminidases derived from Asiatic toad and spiny eel

  2022cites this paper
• Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes

  2022cites this paper
• Pre-Treatment with Zirconia Nanoparticles Reduces Inflammation Induced by the Pathogenic H5N1 Influenza Virus

  2020cites this paper
• Bioassay of ferulic acid derivatives as influenza neuraminidase inhibitors

  2020cites this paper
• Influenza and antiviral resistance: an overview

  2020cites this paper
• Design and synthesis of glycomimetics: Recent advances

  2020cites this paper
• Defining functional neuraminidase inhibitor drug resistance motifs in avian influenza viruses and the consequential impact on virus fitness in chicken cells

  2019cites this paper
• Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase

  2019cites this paper
• Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors

  2019cites this paper
• Design, synthesis and biological evaluation of honokiol derivatives as influenza neuraminidase inhibitors

  2019cites this paper
• Exploration of the 150 Cavity and the Role of Serendipity in the Discovery of Inhibitors of Influenza Virus A Neuraminidase

  2018cites this paper
• Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase

  2018cites this paper
• A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir

  2017cites this paper
• Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design

  2017influential citation
• Identification and understanding of Kinase Activating Missense Mutations

  2017cites this paper
• Drug resistance in influenza A virus: the epidemiology and management

  2017cites this paper